These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1407000)

  • 1. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Haemost; 1991 May; 65(5):560-4. PubMed ID: 1908140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):111-9. PubMed ID: 1719279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U; Sponer G; Strein K
    J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Res; 1991 May; 62(3):137-46. PubMed ID: 1909815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U; Fischer S; Sponer G
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats.
    Martin U; Sponer G; Strein K
    Drug Metab Dispos; 1993; 21(2):236-41. PubMed ID: 8097691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
    Kopia GA; Kopaciewicz LJ; Fong KL; Crysler CS; Boyle K; Ruffolo RR
    J Cardiovasc Pharmacol; 1988 Sep; 12(3):308-16. PubMed ID: 2464103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Lill H; Rudolph R; Sponer G; Stern A; Strein K
    Z Kardiol; 1990; 79 Suppl 3():167-70. PubMed ID: 2129142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.
    Clozel JP; Tschopp T; Luedin E; Holvoet P
    Circulation; 1989 Jan; 79(1):125-33. PubMed ID: 2491972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model.
    Wu Z; Van de Werf F; Stassen T; Mattsson C; Pohl G; Collen D
    J Cardiovasc Pharmacol; 1990 Aug; 16(2):197-203. PubMed ID: 1697374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022.
    Martin U; Sponer G; Strein K
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):455-61. PubMed ID: 7681508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses.
    Bäumer W; Herrling GM; Feige K
    BMC Vet Res; 2013 Aug; 9():158. PubMed ID: 23938183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers.
    Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G
    Clin Pharmacol Ther; 1991 Oct; 50(4):429-36. PubMed ID: 1914379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Craft TJ; Sundboom JL; Grinnell BW; Bobbitt JL; Burck PJ; Quay JF; Smith GF
    Circulation; 1990 Sep; 82(3):930-40. PubMed ID: 2118431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.